FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update